ALLMedicine™ Shigellosis Center

Mar 18th, 2023 - A significant cause of shigellosis in Bangladesh and other developing countries is Shigella flexneri serotype 6. This serotype has been subtyped, on the basis of the absence or presence of a group-specific antigen, E1037, into S. flexneri 6a and 6...

Mar 7th, 2023 - This is a double-blind placebo-controlled randomized-study trial to test the safety, reactogenicity, immunogenicity and efficacy of a 10^6 cfu dose of an oral live-attenuated S. sonnei vaccine candidate, WRSs2, in up to 120 healthy males and non-p...

Mar 3rd, 2023 - Laboratory Studies Hematology The total WBC count reveals no consistent findings. A shift to the left (increased number of band cells) in the differential WBC count in a patient with diarrhea suggests bacillary dysentery. Leukopenia or leukemoid r...

Mar 3rd, 2023 - Medication Summary Various antimicrobial agents are effective in the treatment of shigellosis, although options are becoming limited because of globally emerging drug resistance. Resistance of Shigella species to sulfonamides, tetracyclines, ampic...

Mar 3rd, 2023 - History Populations that are at high-risk for shigellosis include the following: Children in daycare centers (< 5 y) and their caregivers Persons in custodial institutions International travelers Homosexual men People living in crowded conditions ...

Mar 7th, 2023 - This is a double-blind placebo-controlled randomized-study trial to test the safety, reactogenicity, immunogenicity and efficacy of a 10^6 cfu dose of an oral live-attenuated S. sonnei vaccine candidate, WRSs2, in up to 120 healthy males and non-p...

Feb 16th, 2023 - The purpose of this study is to determine if ShigActive is safe and effective in healthy adults in a continuous Phase 1/2a trial. Phase 1 will asses the safety of ShigActive in healthy adults, while Phase 2a will evaluate the safety and efficacy o...

Jan 19th, 2023 - Specific Objectives: Primary objective To determine whether tebipenem-pivoxil is non-inferior to the currently WHO-recommended second line Shigella therapy (ceftriaxone) Secondary objectives: Describe the number of adverse events, between children...

Jun 8th, 2022 - ShigETEC vaccine is intended to stimulate an immune response in which protective antibodies are generated that prevent infection if a vaccinee is subsequently exposed to Shigella and ETEC. Main objective of the study: In Stage 1 is to determine Ma...

Apr 25th, 2022 - The aim of the current clinical study is to evaluate, for the first time in humans (FTIH), the safety and immunogenicity of the altSonflex1-2-3 candidate vaccine against S. sonnei and S. flexneri serotypes 1b, 2a, and 3a. The vaccine will be first...

Feb 24th, 2023 - Healthcare professionals should be on the lookout for an increase in extensively drug-resistant (XDR) Shigella infections (shigellosis) and should report cases to local or state health departments, the CDC said in a health advisory Friday. Given t...

Shigellosis is a highly contagious diarrheal illness caused by the Shigella bacteria. Find out about the disease, people at risk, and steps you can take to prevent infection.

Aug 5th, 2022 - Two acute gastrointestinal illness outbreaks were linked to a splash pad at a Kansas wildlife park, with 21 kids sickened with shigellosis and six with norovirus, a CDC report showed. According to an investigation with Kansas state and county publ...

Sep 22nd, 2021 - Evacuees of Afghanistan who have arrived in the United States must be vaccinated against measles and undergo quarantine for 21 days, according to a health advisory issued September 20 by the Centers for Disease Control and Prevention (CDC). At the...

Aug 7th, 2018 - General supportive care of patients with shigellosis includes: Infection with Shigella is normally self-limited. The average duration of gastrointestinal symptoms of untreated shigellosis is 7 days Antibiotic treatment is indicated in some patient...